BioSpace News Archive

Ironwood Pharmaceuticals, located in Cambridge, Massachusetts, released its second-quarter financial report and updated its business activities. Key among the announcements was the termination of a license deal with AstraZeneca for its lesinurad franchise.

Imprimis Pharmaceuticals, Inc. reported results for the second quarter 2018.

Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the completion of enrollment of its Phase 2b CaLIPSO clinical trial investigating Sanifit’s lead candidate SNF472, for the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients on haemodialysis (HD).

Initiated ADVANCE Phase 3 Program for Ralinepag in Pulmonary Arterial Hypertension (PAH)

Updates 2018 Full Year Guidance

2nd Quarter Revenue of $1,416 Million, an increase of 26%, Net (Loss) Income Attributable to Diplomat of $(4.0) Million compared to $3.6 Million, Adjusted EBITDA of $42.7 Million, an increase of 70%

Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes.

Initiated the Phase 1/1b program for AB928 combinations; Initial dose-escalation data for all four combinations expected in the first half of 2019

Strength of Business Transformation Efforts Continue to Drive Revenue, Profit Growth

BWX Technologies, Inc. announced that it has completed the acquisition of Sotera Health’s Nordion medical isotope business.